期刊
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY
卷 30, 期 1, 页码 22-38出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.berh.2016.03.004
关键词
Connective tissue disease; Pulmonary arterial hypertension; Pulmonary hypertension; Systemic sclerosis; Early detection; Screening; Diagnosis; Treatment; Survival; Review
类别
资金
- Actelion Australia
- GlaxoSmithKline
- Scleroderma Australia
- Arthritis Australia
- Bayer
- CSL Biotherapies
- GlaxoSmithKline Australia
- Pfizer
- Menarini Pharmaceuticals
Over the past two decades, there have been several advances in the assessment and management of connective tissue disease-related pulmonary arterial hypertension (CTD-PAH) that improved outcomes of the treatment of this lethal disease, and this will be the focus of this study. Systemic sclerosis is the leading cause of CTD-PAH, followed by systemic lupus erythematosus, mixed connective tissue disease, idiopathic inflammatory myositis, rheumatoid arthritis, and Sjogren's syndrome. Clinical registries have been invaluable in informing about the burden of disease, risk and prognostic factors, and temporal trends with respect to treatment and outcome in CTD-PAH. The major advances have centered on improved disease classification and diagnostic criteria, screening and early diagnosis, the emergence of evidence-based therapies including combination goal-orientated treatment strategies, and the establishment of centers with expertise in PAH. Crown Copyright (C) 2016 Published by Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据